Jennifer Morton
Nurse Practitioner · Maryville, TNNPI 1407899446
Payments from drug & device makers
Across 187 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- Neurocrine Biosciences, Inc.$377
- Lilly USA, LLC$355
- Bayer$336
- Pfizer$305
- Otsuka America Pharmaceutical, Inc.$260
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $447 |
| Neurocrine Biosciences, Inc. | 14 | $377 |
| Lilly USA, LLC | 18 | $355 |
| Bayer | 15 | $336 |
| Pfizer | 20 | $305 |
| Otsuka America Pharmaceutical, Inc. | 13 | $260 |
| GSK | 11 | $199 |
| Eisai Inc. | 8 | $177 |
| Sumitomo Pharma America, Inc. | 8 | $150 |
| E.r. Squibb & Sons, L.L.C. | 9 | $138 |
| AstraZeneca | 7 | $110 |
| Lundbeck LLC | 4 | $107 |
| Corium, LLC | 5 | $94 |
| Novartis | 4 | $80 |
| Boehringer Ingelheim | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $44 |
| UCB, Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Merck | 2 | $29 |
| Boston Scientific | 1 | $25 |
| Inogen, Inc. | 1 | $25 |
| Organogenesis Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| CMP Pharma, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$122
How this compares
$3,705 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $90,496 |
| EliquisApixaban | 68 | $80,748 |
| OzempicSemaglutide | 45 | $67,764 |
| MounjaroTirzepatide | 23 | $31,071 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $28,393 |
| XareltoRivaroxaban | 24 | $26,816 |
| JardianceEmpagliflozin | 19 | $25,621 |
| GemtesaVibegron | 25 | $22,473 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $17,870 |
| MyrbetriqMirabegron | 19 | $15,631 |
| Potassium Chloride | 124 | $2,328 |
| Atorvastatin Calcium | 220 | $2,278 |
| Levothyroxine Sodium | 180 | $2,082 |
| Mirtazapine | 58 | $1,851 |
| Pantoprazole Sodium | 157 | $1,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $377 | $90,49612 claims |
| PfizerEliquis | $305 | $80,74868 claims |
| Novo NordiskOzempic | $447 | $67,76445 claims |
| Lilly USA, LLCMounjaro | $355 | $31,07123 claims |
| Boehringer IngelheimJardiance | $72 | $25,62119 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $150 | $22,47325 claims |
| GSKTrelegy Ellipta | $199 | $17,87016 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $15,63119 claims |
| AbbVieSynthroid | $21 | $1,66514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Maryville
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.